Merck Sharp + Dohme Corp.

Oncoethix Gmbh

Cyclacel Limited

Eric Raymond

Francesco Bertoni

Ian Fleming

Maria Eugenia Riveiro

Simon Green

A method of treating non-small cell lung cancer and/or small cell lung cancer in a mammal comprises the step of administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1). 

Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds

A method of treating non-small cell lung cancer in a mammal by administering to a patient a pharmaceutically acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein Ris alkyl having a carbon number of 1-4, Ris a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, Ris a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; &#x2014;NR&#x2014;(CH)&#x2014;Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and Ris phenyl or pyridyl optionally substituted by a halogen atom; or &#x2014;NR&#x2014;CO&#x2014;(CH)&#x2014;Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Ris phenyl or pyridyl optionally substituted by a halogen atom, and Ris &#x2014;(CH)&#x2014;CO&#x2014;NH&#x2014;Rwherein a is an integer of 1-4, and Ris alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or &#x2014;(CH)&#x2014;COORwherein b is an integer of 1-4, and Ris alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. 

Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds

A method of treating leukemia in a mammal by administering a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) wherein Ris alkyl having a carbon number of 1-4, Ris a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, Ris a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; &#x2014;NR&#x2014;(CH)&#x2014;Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and Ris phenyl or pyridyl optionally substituted by a halogen atom; or &#x2014;NR&#x2014;CO&#x2014;(CH)&#x2014;Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Ris phenyl or pyridyl optionally substituted by a halogen atom, and Ris &#x2014;(CH)&#x2014;CO&#x2014;NH&#x2014;Rwherein a is an integer of 1-4, and Ris alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or &#x2014;(CH)&#x2014;COORwherein b is an integer of 1-4, and Ris alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. 

Growing community of inventors

Noiseau, France

Eric Raymond